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The design, synthesis, and in vitro evaluation of the first macrocyclic inhibitor of 3C and 
3C-like proteases of picornavirus, norovirus, and coronavirus are reported. The in vitro 
inhibitory activity (50% effective concentration) of the macrocyclic inhibitor toward 
enterovirus 3C protease (CVB3 Nancy strain), and coronavirus (SARS-CoV) and 
















The picornavirus-like protease supercluster includes viruses in the Picornaviridae, 
Coronaviridae, and Caliciviridae families. Many human pathogens of major medical and 
economic importance belong to these virus families. For instance, the family 
Picornaviridae includes enterovirus (enterovirus, EV; coxsackievirus, CV; poliovirus, 
PV), human rhinovirus (HRV), and hepatovirus (hepatitis A virus, HAV).1-2 Non-polio 
enteroviruses are responsible for 10-15 million symptomatic infections in the U.S. each 
year,3 while HRV is the major causative agent of upper respiratory tract infections.4 In 
the Coronaviridae family, severe acute respiratory syndrome (SARS) caused by SARS-
coronavirus (SARS-CoA) is a recognized global threat to public health.5 Noroviruses 
belong to the Norovirus genus of the Caliciviridae family and are highly contagious 
human pathogens that are the most common cause of food borne and water borne 
acute viral gastroenteritis.6 Thus, norovirus infection constitutes an important public health 
problem. There are currently no vaccines (except for poliovirus) or specific antiviral 
agents for combating infections caused by the aforementioned viruses; thus, there is an 
urgent and unmet need for the discovery and development of broad spectrum small-
molecule therapeutics and prophylactics for these important pathogens.7-10 
The picornaviral genome consists of a positive sense, single-stranded RNA of ~7.5 kb in 
length that encodes a large precursor polyprotein that requires proteolytic processing to 
generate mature viral proteins.1-2 Processing of the polyprotein is primarily mediated by 
the viral 3C protease (3Cpro). Although there is high genetic diversity among 
picornaviruses, 3Cpro is invariant, as well as essential for virus replication. Likewise, the 
~ 30 kb genome of SARS-CoV comprises both nonstructural and structural regions. 
Two polyproteins (designated as pp1a and pp1ab) encoded by the viral genome 
undergo proteolytic processing by two proteases: a chymotrypsin-like cysteine protease 
(3C-like protease, 3CLpro) and a papain-like protease (PLpro), to generate functionally 
active proteins. Lastly, the 7-8 kb RNA genome of noroviruses encodes a polyprotein 
that is processed by 3C-like protease (3CLpro) to generate mature proteins.11 
Inspection of the crystal structures of picornavirus 3Cpro12-15 and norovirus 3CLpro,16-19 
reveals that the proteases share in common a chymotrypsin-like fold, a Cys-His-Glu/Asp 
catalytic triad (EV and CV 3Cpro, and NV 3CLpro) or Cys-His dyad (SARS-CoV 
3CLpro),20 an extended binding site, and a preference for cleaving at Gln-Gly (P1-P1’) 
junctions in protein and synthetic peptidyl substrates (vide infra). The confluence of 
structural similarities in the active sites, mechanism of action, and substrate specificity 
preferences of EV and CV 3Cpro,12-13 SARS-CoV 3CLpro,20-21 and NV 3CLpro11,17,22 
(Table 1) suggests that a drug-like entity can be fashioned that displays inhibitory 
activity against all three proteases, making them appealing targets for the discovery of 
broad spectrum antiviral agents.16,23  
Table 1 
Picornavirus 3Cpro,2 SARS-CoV 3CLpro23 and NV 3CLpro24 have been the subject of 
intense investigations. We report herein the design, synthesis, and in vitro evaluation of 
a representative member of a new class of macrocyclic transition state inhibitors (I) 
(Figure 1) that is effective against all three proteases. To our knowledge, this is the first 
report describing the inhibition of 3Cpro and 3CLpro of pathogens belonging to the 
picornavirus-like protease supercluster, by a macrocyclic inhibitor. 
Figure 1 
The design of macrocyclic inhibitor (I) rested on the following considerations: (a) 
proteases are known to recognize their ligands in the β-strand conformation;25 (b) 
macrocyclization is an effective way of pre-organizing a peptidyl transition state mimic in 
a β-strand  conformation suitable for binding to the active site of a protease;26-28 (c) in 
general, macrocyclization increases affinity, cellular permeability, and proteolytic 
stability;29 (d) macrocyclization improves drug-like characteristics;30-31 (e) the plasticity of 
the S3 subsite in the 3C and 3CL proteases was exploited in the design of macrocyclic 
inhibitor (I) by tethering the P1 Gln side chain to the P3 residue side chain; and, (e)  
computational and modeling studies suggested that a ring size corresponding to n = 3 
would produce good receptor binding and minimal intra-ligand strain.    
Based on the aforementioned considerations, inhibitor (I) was assembled in a 
convergent fashion by first constructing fragments 2 and 4, followed by subsequent 
coupling of the two fragments to generate acyclic precursor 5 (Scheme 1). Cyclization 
Scheme 1 
 was subsequently accomplished using click chemistry.32-35 Thus, fragment 2 was 
synthesized by coupling (L) Boc-protected propargyl glycine with (L) leucine methyl 
ester using EDCI/HOBt/DIEA/DMF to yield the dipeptidyl ester which was subsequently 
treated with dry HCl in dioxane to remove the N-terminal Boc protecting group. Reaction 
with benzylchloroformate yielded the Cbz-protected ester which was hydrolyzed with 
LiOH in aqueous THF to yield the corresponding acid 2. EDCI-mediated coupling of 
commercially available (L) Boc-Glu-OCH3 with NH2(CH2)nN3 (n=3), followed by removal 
of the Boc group, yielded fragment 4.36 The amino alkyl azide was conveniently 
synthesized by converting BocNH(CH2)nOH to the mesylate via treatment with 
methanesulfonyl chloride in the presence of triethylamine, followed by reaction with 
sodium azide in DMF and removal of the protective group. Coupling of  fragments 2 with 
4 using standard coupling conditions yielded acyclic precursor 5 which was treated with 
Cu(I)Br/DBU in dichloromethane to furnish  compound 6 in 45% yield. Compound 6 was 
treated with lithium borohydride to yield alcohol 7 (84% yield) which, upon Dess-Martin 
periodinane oxidation37, and subsequent purification gave macrocyclic aldehyde 8 
(Scheme 1, structure (I), n = 3, R = isobutyl, X = CHO), as a white solid.38 The inhibitory 
activity of aldehyde 8 was evaluated in vitro as previously described.16,39-42 Compound 8 
displayed inhibitory activity against NV 3CLpro (IC50 5.1 µM), enterovirus (CVB3 Nancy 
strain) 3Cpro (1.8 µM), and SRAS-CoV 3CLpro (IC50 15.5 µM).  
In order to gain insight and understanding into the binding of inhibitor 8 to the active site 
of each protease, computer modeling was used. Thus, the receptor structures were 
prepared from the following protein data bank (PDB) crystal structures:  A) NV 3CLpro 
from 2IPH,17 B) CV 3C pro from 3ZZB,43 and  C) SARS-CoV 3CLpro from 2ZU5.44 
These three receptor models were chosen by virtue of having cocrystallized ligands that 
each displayed the following three features consistent with the likely binding mode of 
inhibitor 8: i) a covalent attachment to the catalytically active cysteine (analogous to the 
terminal aldehyde in inhibitor 8), ii) branched alkyl, as per isobutyl group in 8, and iii) 
aryl (phenylalanine or Cbz), as per Cbz in 8. This permitted the intelligent prepositioning 
of inhibitor 8 into each of the three protease receptors, which was accomplished in 
Pymol45 via manual docking. Pymol was then used to produce a computational 
framework for refining the docked conformation as follows: a ligand-receptor complex 
was generated by protonating the preliminary receptor-ligand complex (according to 
physiological pH with anionic aspartate and glutamate residues, and cationic lysine and 
arginine residues), then retaining only the ligand plus all complete residues with at least 
one atom located within no more than 6.0 Å from any ligand atom.  The resulting 
complex models were then permitted to undergo 1000 molecular mechanics 
optimization steps in Avogadro46 using the MMFF94 force field and electrostatic charge 
model.47  The resulting complexes were then rendered in PyMol. The computational 
studies indicate that inhibitor 8 is capable of nestling snugly in the active site of the 3C 
and 3CL proteases.    
In summary, we report herein for the first time the inhibition of the 3Cpro and 3CL pro of 
viral pathogens belonging to the picornavirus-like protease supercluster by a 
macrocyclic inhibitor. A full account describing the exploration of R, linker, n (ring size), 
and the nature of warhead X, will be reported in due course.       
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Substrate specificity of the 3C and 3C-like proteases of viruses in the picornavirus-
like protease supercluster.  
 
Viral 3Cpro or 
3CLpro 
P5 P4 P3 P2 P1 P1’ P2’ 
EV71 E A V/L/T L/F Q G P 
CVA16 E A L F Q G P 
SARS-CoV S A V/T/K L Q A/S G 





















































Figure 1. General structure of macrocyclic inhibitor (I). 
Figure 2. Computationally predicted conformers for inhibitor 8 bound to A) Norovirus 
3CLpro, B) Coxsackie virus 3Cpro, and  C) SARS-CoV 3CLpro.  Inhibitor is rendered 
as CPK-colored sticks with black carbon atoms.  Protein receptors are shown as 
Connolly surfaces colored as follows:  yellow = nonpolar aryl, alkyl and thioalkyl; 
white = weakly polar aryl and alkyl; cyan = polar H; blue = polar N; red = polar O.  
 
